Sponsored For
Beginners Choice

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Novavax, Inc is a biotechnology business based in the US. Novavax shares (NVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Novavax employs 522 staff and has a trailing 12-month revenue of around USD$204.8 million.
52-week range | USD$6.26 - USD$189.4 |
---|---|
50-day moving average | USD$122.7806 |
200-day moving average | USD$115.7402 |
Wall St. target price | USD$188.5 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-8.597 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the last close of $N/A
1 week (2021-01-13) | N/A |
---|---|
1 month (2020-12-20) | N/A |
3 months (2020-10-20) | N/A |
6 months (2020-07-20) | N/A |
1 year (2020-01-20) | N/A |
---|---|
2 years (2019-01-20) | N/A |
3 years (2018-01-20) | N/A |
5 years (2016-01-20) | N/A |
Revenue TTM | USD$204.8 million |
---|---|
Gross profit TTM | USD$-95,180,000 |
Return on assets TTM | -8.19% |
Return on equity TTM | -468.16% |
Profit margin | -133.1% |
Book value | $1.691 |
Market capitalisation | USD$8.1 billion |
TTM: trailing 12 months
There are currently 7.3 million Novavax shares held short by investors – that's known as Novavax's "short interest". This figure is 1.3% up from 7.2 million last month.
There are a few different ways that this level of interest in shorting Novavax shares can be evaluated.
Novavax's "short interest ratio" (SIR) is the quantity of Novavax shares currently shorted divided by the average quantity of Novavax shares traded daily (recently around 5.0 million). Novavax's SIR currently stands at 1.48. In other words for every 100,000 Novavax shares traded daily on the market, roughly 1480 shares are currently held short.
However Novavax's short interest can also be evaluated against the total number of Novavax shares, or, against the total number of tradable Novavax shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novavax's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Novavax shares in existence, roughly 120 shares are currently held short) or 0.1155% of the tradable shares (for every 100,000 tradable Novavax shares, roughly 116 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novavax.
Steps to owning and managing Vaxart shares from Ireland.
Steps to owning and managing Takeda Pharmaceutical shares from Ireland.
Steps to owning and managing Sinovac Biotech Ltd shares from Ireland.
Steps to owning and managing Mesoblast shares from Ireland.
Steps to owning and managing Inovio Pharmaceuticals shares from Ireland.
Steps to owning and managing Heat Biologics shares from Ireland.
Steps to owning and managing CytoDyn shares from Ireland.
Steps to owning and managing Cynata Therapeutics shares from Ireland.
Steps to owning and managing BioNTech shares from Ireland.
Steps to owning and managing Atomo Diagnostics shares from Ireland.